A case of severe COVID-19 in a patient with progressive fibrosing interstitial lung disease
L. A. Akulkina,
M. Yu. Brovko,
A. A. Schepalina,
V. I. Sholomova,
A. A. Kitbalian,
A. S. Moiseev,
P. P. Potapov,
S. V. Moiseev https://doi.org/10.18093/0869-0189-2022-32-5-763-769
Abstract
Interstitial lung diseases (ILDs) is a wide group of diffuse parenchymal lung diseases that can lead to interstitial pulmonary fibrosis. Clinical course of all ILDs, in particular with chronic fibrosing phenotype, can be complicated by an acute exacerbation caused by infection. Today, data about clinical course of COVID-19 in patients with progressive interstitial lung diseases is limited. In this case we described the course of COVID-19 infection in a patient with an interstitial pneumonia with autoimmune features (IPAF) and a progressive pulmonary fibrosis (PPF). We also discussed the typical features of COVID-19 in this population and the directions for further research.
About the Authors
L. A. Akulkina
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Larisa A. Akulkina, Assistant Lecturer, Department of Internal Diseases, Occupational Diseases and Rheumatology, Institute of Clinical Medicine, pulmonologist, E.M.Tareev Clinic of Rheumatology, Internal and Occupational Diseases, University Hospital No.3
ul. Trubetskaya 8, build. 2, Moscow, 119991
Competing Interests:
The authors declare absence of conflict of interests.
M. Yu. Brovko
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Mikhail Yu. Brovko, Candidate of Medicine, pulmonologist, Deputy Chief Physician for Medicine, University Hospital No.3
ul. Trubetskaya 8, build. 2, Moscow, 119991
Competing Interests:
The authors declare absence of conflict of interests.
A. A. Schepalina
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Anastasia A. Shchepalina, Post-Graduate Student, Department of Internal Diseases, Occupational Diseases and Rheumatology, Institute of Clinical Medicine
ul. Trubetskaya 8, build. 2, Moscow, 119991
Competing Interests:
The authors declare absence of conflict of interests.
V. I. Sholomova
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Competing Interests:
Russian Federation
Viktoriya I. Sholomova, Head of Department of Pulmonology and Occupational Diseases, E.M.Tareev Clinic of Rheumatology, Internal and Occupational Diseases, University Hospital No.3
ul. Trubetskaya 8, build. 2, Moscow, 119991
Competing Interests:
The authors declare absence of conflict of interests.
A. A. Kitbalian
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University);
Federal State Budget Educational Institution of Higher Education M.V.Lomonosov Moscow State University
Russian Federation
Competing Interests:
Russian Federation
Aram A. Kitbalyan, Post-Graduate Student, Department of Internal Diseases, Faculty of Basic Medicine, Federal State Budget Educational Institution of Higher Education M.V.Lomonosov Moscow State University
ul. Trubetskaya 8, build. 2, Moscow, 119991,
Leninskye gory 1, Moscow, 11999
Competing Interests:
The authors declare absence of conflict of interests.
A. S. Moiseev
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University);
Federal State Budget Educational Institution of Higher Education M.V.Lomonosov Moscow State University
Russian Federation
Competing Interests:
Russian Federation
Alexey S. Moiseev, pulmonologist, Department of Pulmonology and Occupational Diseases, E.M.Tareev Clinic of Rheumatology, Internal and Occupational Diseases, University Hospital No.3, Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Post-Graduate Student, Department of Internal Diseases, Faculty of Basic Medicine, Federal State Budget Educational Institution of Higher Education M.V.Lomonosov Moscow State University
ul. Trubetskaya 8, build. 2, Moscow, 119991,
Leninskye gory 1, Moscow, 11999
Competing Interests:
The authors declare absence of conflict of interests.
P. P. Potapov
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University);
Federal State Budget Educational Institution of Higher Education M.V.Lomonosov Moscow State University
Russian Federation
Competing Interests:
Russian Federation
Pavel P. Potapov, pulmonologist, E.M.Tareev Clinic of Rheumatology, Internal and Occupational Diseases, University Hospital No.3, Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Post-Graduate Student, Department of Internal Diseases, Faculty of Basic Medicine, Federal State Budget Educational Institution of Higher Education M.V.Lomonosov Moscow State University
ul. Trubetskaya 8, build. 2, Moscow, 119991,
Leninskye gory 1, Moscow, 11999
Competing Interests:
The authors declare absence of conflict of interests.
S. V. Moiseev
Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University);
Federal State Budget Educational Institution of Higher Education M.V.Lomonosov Moscow State University
Russian Federation
Competing Interests:
Russian Federation
Sergey V. Moiseev, Doctor of Medicine, Professor, Department of Internal Diseases, Occupational Diseases and Rheumatology, Institute of Clinical Medicine, Director of E.M.Tareev Clinic of Rheumatology, Internal and Occupational Diseases, University Teaching Hospital No.3, Federal State Autonomous Educational Institution of Higher Education I.M.Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University); Professor, Department of Internal Diseases, Faculty of Basic Medicine, Federal State Budget Educational Institution of Higher Education M.V.Lomonosov Moscow State University
ul. Trubetskaya 8, build. 2, Moscow, 119991,
Leninskye gory 1, Moscow, 11999
Competing Interests:
The authors declare absence of conflict of interests.
References
1. Antoniou K.M., Margaritopoulos G.A., Tomassetti S. et al. Interstitial lung disease. Eur. Respir. Rev. 2014; 23 (131): 40–54. DOI: 10.1183/09059180.00009113.
2. Wijsenbeek M., Cottin V. Spectrum of fibrotic lung diseases. N. Engl. J. Med. 2020; 383 (10): 958–968. DOI: 10.1056/nejmra2005230.
3. Trofimenko I.N., Chernyak B.A. [Lung lesions in connective tissue diseases]. Pulʹmonologiya. 2019; 29 (5): 604–611. DOI: 10.18093/0869-0189-2019-29-5-604-611 (in Russian).
4. Gulati M. Diagnostic assessment of patients with interstitial lung disease. Prim. Care Respir. J. 2011; 20 (2): 120–127. DOI: 10.4104/pcrj.2010.00079.
5. Avdeev S.N. [Idiopathic pulmonary fibrosis]. Pul’monologiya. 2015; 25 (5): 600–612. DOI: 10.18093/0869-0189-2015-25-5-600-612 (in Russian).
6. George P.M., Spagnolo P., Kreuter M. et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respir. Med. 2020; 8 (9): 925–934. DOI: 10.1016/S2213-2600(20)30355-6.
7. Avdeev S.N., Chikina S.Yu., Nagatkina O.V. [Idiopathic pulmonary fibrosis: a new international clinical guideline]. Pulʹmonologiya. 2019; 29 (5): 525–554. DOI: 10.18093/0869-0189-2019-29-5-525-552 (in Russian).
8. Kondoh Y., Kataoka K., Ando M. et al. COVID-19 and acute exacerbation of interstitial lung disease. Respir. Investig. 2021; 59 (5): 675–678. DOI: 10.1016/j.resinv.2021.06.007.
9. Leuschner G., Behr J. Acute exacerbation in interstitial lung disease. Front. Med. (Lausanne). 2017; 4: 176. DOI: 10.3389/fmed.2017.00176.
10. Chams N., Chams S., Badran R. et al. COVID-19: a multidisciplinary review. Front. Public Health. 2020; 8: 383. DOI: 10.3389/fpubh.2020.00383.
11. Gao Y.D., Ding M., Dong X. et al. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy. 2021; 76 (2): 428–455. DOI: 10.1111/all.14657.
12. Podolanczuk A.J., Richeldi L. COVID-19 and interstitial lung disease: keep them separate. Am. J. Respir. Crit. Care Med. 2020; 202 (12): 1614–1616. DOI: 10.1164/rccm.202010-3918ED.
13. Gallay L., Uzunhan Y., Borie R. et al. Risk factors for mortality after COVID-19 in patients with preexisting interstitial lung disease. Am. J. Respir. Crit. Care Med. 2021; 203 (2): 245–249. DOI: 10.1164/rccm.202007-2638LE.
14. Yang J., Zheng Y., Gou X. et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int. J. Infect. Dis. 2020; 94: 91–95. DOI: 10.1016/j.ijid.2020.03.017.
15. Esposito A.J., Menon A.A., Ghosh A.J. et al. Increased odds of death for patients with interstitial lung disease and COVID-19: a case-control study. Am. J. Respir. Crit. Care Med. 2020; 202 (12): 1710–1713. DOI: 10.1164/rccm.202006-2441LE.
16. Drake T.M., Docherty A.B., Harrison E.M. et al. ISARIC4C investigators. Outcome of hospitalization for COVID-19 in patients with interstitial lung disease: аn international multicenter study. Am. J. Respir. Crit. Care Med. 2020; 202 (12): 1656–1665. DOI: 10.1164/rccm.202007-2794OC.
17. Listing J., Gerhold K., Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology. 2013; 52 (1): 53–61. DOI: 10.1093/rheumatology/kes305.
18. Hasseli R., Mueller-Ladner U., Hoyer B.F. et al. Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases. RMD Open. 2021; 7 (1): e001464. DOI: 10.1136/rmdopen-2020-001464.
19. Brenner E.J., Ungaro R.C., Gearry R.B. et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020; 159 (2): 481–491.e3. DOI: 10.1053/j.gastro.2020.05.032.
20. Gianfrancesco M., Hyrich K.L., Al-Adely S. et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann. Rheum. Dis. 2020; 79 (7): 859–866. DOI: 10.1136/annrheumdis-2020-217871.
Supplementary files
Review
For citations:
Akulkina L.A., Brovko M.Yu., Schepalina A.A., Sholomova V.I., Kitbalian A.A., Moiseev A.S., Potapov P.P., Moiseev S.V. A case of severe COVID-19 in a patient with progressive fibrosing interstitial lung disease. PULMONOLOGIYA. 2022;32(5):763-769. (In Russ.) https://doi.org/10.18093/0869-0189-2022-32-5-763-769
Views:
481
Email this article 